Page 1,070«..1020..1,0691,0701,0711,072..1,0801,090..»

Panic-buying for coronavirus affects diabetes patients: They can’t find rubbing alcohol – USA TODAY

Posted: April 8, 2020 at 10:43 am

The coronavirus pandemic has caused toilet paper shortages and long lines, but panic buying is not a new phenomenon and it certainly isnt helping. USA TODAY

While the masses hunt for toilet paper, Caroline Gregory and other people with diabetes are on a different mission: scouring stores for the rubbing alcohol or alcohol swabs needed to manage their disease.

Gregory stopped in Carlie Cs, Dollar General and Harris Teeter in Fayetteville, North Carolina, in pursuit of this vital component of her medical routine.

Were all supposed to be staying at home, and Im out going to 10 different stores, said Gregory, 33, whose diabetes could heighten her risk for COVID-19 complications. Thats also not safe.

Rubbing alcohol and alcohol swabs or wipes are the latest products swept up by the nations demand for anything and everything seen as a disinfectant against the novel coronavirus by hospitals and average consumers alike.

This is what China did to beat coronavirus: Experts say America couldn't handle it

Andy Lerman, vice president of operations for Hydrox Laboratories, a manufacturer based outside Chicago, said the majority of the low-profit-margin medical product his company makes is headed to hospitals, which are going through it faster than they have in the past. He has seen distributors order more than five times the amount they typically do.

Hospitals are wiping down everything all the time with every type of virucide that they have at their disposal, he said. Im making it as fast as I can, but I have more orders than I have capacity to manufacture.

Isopropyl alcohol a primary ingredient in some types of rubbing alcohol has been touted as a cleaner that neutralizes the coronavirus on everything from kitchen countertops to phones. After the depletion of supplies of hand sanitizer, also seen as a defense against COVID-19, demand exploded to make homemade versions. The Food and Drug Administration and the World Health Organization list isopropyl alcohol as a critical ingredient in their recommended recipes.

There is a lot of misinformation out there about coronavirus. We sort the facts from falsehoods. Wochit

For those with diabetes or other chronic medical conditions, the general publics resulting panic-buying spree has threatened their medical routines, such as when patients use an alcohol swab or a rubbing-alcohol-soaked cotton ball to disinfect their skin before they inject insulin.

Alternatives such as witch hazel may not have the same antiviral properties, and the proof of most brands of vodka isnt high enough to be effective. Other compounds, such as hydrogen peroxide and liquid iodine, can be unwieldy for diabetes patients to manage while changing insulin pump sites on the go, Gregory said.

Coronavirus coloring book from St. Jude Childrens Research Hospital: Helping kids understand COVID-19

Despite the inability to obtain their usual products, people with diabetes need to maintain their blood sugar levels, said Kelly Mueller, vice president of community impact at the American Diabetes Association. She encouraged patients to wash their hands and pump sites carefully and let them air-dry.

In the midst of the coronavirus panic, the problem is compounded by a dearth of antibacterial soap or hand sanitizer to replace the disinfecting swabs or rubbing alcohol needed to keep prick sites clean, said Alison Dvorchik. She lives in Orlando, Florida, with her 17-year-old son, Matthew, who has Type 1 diabetes.

Im worried for the entire Type 1 diabetic community, she said. Thats a cesspool of infection waiting to happen.

Any potential infection is a strain on an overburdened health care system, Dvorchik said. Shes trying to ward off that fate for Matthew with a stash of 100 alcohol wipes from a friend they use about three a day with Matthews insulin pump.

The madness began about three weeks ago, according to New Jersey-based AvaCare Medical CEO Steven Zeldes, who runs one of the nations larger online medical supply companies.

Overnight, his site was swamped with thousands and thousands of orders around the country for rubbing alcohol and rubbing alcohol swabs medical supply items that had not been a primary focus for the company.

At first, he suspected some sort of pricing mishap. Thenhe realized rubbing alcohol was a primary ingredient in making homemade hand sanitizer.

The tsunami of orders cleared out the warehouses of AvaCare Medicals distributors in less than two days. Zeldes said the company was out of stock so fast that it received thousands of orders before being able to take down the listings.

Our company was always a medical supply company for seniors or nursing homes or hospitals, Zeldes said. Now were a company for every single citizen of America.

Cathi Carothers, an operations assistant at Lab Alley, a chemical supplier in Austin, Texas, said her company saw a similar explosion of interest in alcohol products from fire departments and post offices as well as Tesla, the Department of Homeland Security and Johns Hopkins University.

No one could have anticipated this much demand in a month, Carothers said.

'Its time to save people': Synagogue members who had coronavirus donate blood to help others

When Lab Alley called Dow and ExxonMobil two of the largest raw-component manufacturers of isopropyl alcohol in the USA to procure more, she said, the companies told Lab Alley they prioritize hospitals.

Dow confirmed to Kaiser Health News it worked with the FDA and state officials to maximize production of all its high-demand products. ExxonMobil directed Kaiser Health News to a news release stating it workedwith hard-hit New York and Louisiana to send isopropyl alcohol from its Baton Rouge Chemical Plant, which it said is home to the worlds largest isopropyl alcohol production site.

Medline, a major supplier in Chicago, and New Jersey-based Becton, Dickinson, a health care product manufacturer and supplier, felt the crush of demand. Medline spokesperson Stacy Rubenstein cited a 100% increase in March this year over last. Accordingly, both companies said they have ramped up production and enforced fair distribution measures.

Down the supply chain, Gregory, the Fayetteville woman with diabetes, said she lost it in line at Walgreens when she saw a sign saying the store limited customers to four bottles, which is more than she would go through in a year. (She uses it several times weekly to disinfect the sites of her insulin pump and every 10 days for her glucose monitor.)

How much hand sanitizer are you making? Gregory asked. You certainly dont need to be cleaning your kitchen with it its not necessary. I think people are just panicking.

Many forms of rubbing alcohol were sold out on Walgreens online site as of Sunday. Target and Rite Aidalso sold out of some rubbing alcohol and related products online.

Finally, Gregory was able to snag one of the last orders for 100 wipes available through Healthcare Supply Pros, an online medical supply company. It should last her for about five months. She fears for older, poorer people with diabetes who may not have internet access or the money to do the same.

Similar listings show the product is sold out.

Dont hoard something that you dont really need, said Dvorchik, the mother of the teenager with diabetes. Because the people who really need it cant get it.

Kaiser Health News (KHN) is a nonprofit, editorially independent program of the Kaiser Family Foundation that is not affiliated with Kaiser Permanente.

Poll: About 6 in 10 voters say Trump was not prepared for coronavirus outbreak

Coronavirus shakes up employment scene: Here are the companies that are mass-hiring

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/news/health/2020/04/03/rubbing-alcohol-panic-buying-affects-diabetes-patients-amid-pandemic/5106401002/

More:
Panic-buying for coronavirus affects diabetes patients: They can't find rubbing alcohol - USA TODAY

Posted in Diabetes | Comments Off on Panic-buying for coronavirus affects diabetes patients: They can’t find rubbing alcohol – USA TODAY

‘I Lost 125 Lbs. With This Low-Carb Diet And Finally Got Off Diabetes Medication I Was On Since My Teens’ – Yahoo Lifestyle

Posted: April 8, 2020 at 10:43 am

From Women's Health

My name is Samara McKellar (@samara.fit.wlj), and I am 21 years old. I live in Kansas City, Missouri, and I am in college working towards my degree in early childhood education. After having to go on blood sugar medication and struggling to find clothes I felt comfortable going out in, I realized my weight was holding me back. I decided to change my eating habits and lifestyle, and I've lost 125 pounds.

My weight issues have always been apparent in my life. When I was younger, I was slightly overweight, and it made me uncomfortable at times. When I was around 12 years old, I went to an endocrinologist for a check-up, since both of my parents are diabetic. They never officially diagnosed me as pre-diabetic, but my hemoglobin A1C levels (used to screen for diabetes) were high enough to put me on medication to try and lower them and keep me out of the diabetes range.

As I got older, I went from being overweight to medically obeseto then being identified by doctors as morbidly obese. I would try out unhealthy fad diets in high school that would only last a week at most, then I would overeat after giving up. I had many supportive friends and peers in high school, but there were definitely people who also made rude comments that made me feel less-than due to my weight and looks. I saw food as a comforting way to deal with my emotions.

I was 18 years old and 294 poundsand I was trying to find an outfit to wear to a get together with friends. I was getting so upset about how I looked in everything, and how I felt about myself. I couldnt confidently go out and wear the clothes that I found most girls my age wore. I decided in that moment that I had to stop feeling this way and living out that scenario.

On the first day of January 2018, I told myself that I would work on boosting my self-esteem and my health. I would really try to eat healthier, and just start with one habit at a time.

There are *so many* low-calorie foods that are still very dense. This helped me a lot in the beginning because it was hard for my body to adjust from over-eating a ton of food to eating a healthy amount for my weight. However, eating lots of foods like fruits, vegetables, and eggs helped me to feel full for longer, even though they were low calorie.

I chose an eating plan that recommended using a calorie calculator and determined how many calories I could have a day if I wanted to lose one to two pounds a week. I followed that range of calories and used apps like Carb Manager to help me track my foods. I liked the Carb Manager app because it easily displayed calories as well as macronutrients. I also followed a low-carb diet that allowed for about 50 net carbs a day.

I also cut out almost all beverages with added sugar. Before I started trying to change my habits, there were days Id have two sweet teas or lots of soda. Now, I stick to water, green tea, and Crystal Light beverages. I realized the empty calories in sugary drinks never actually filled me up.

I believe that weight loss is 80 percent diet and 20 percent exercise. Going to the gym helped motivate me to keep my eating on track. I wanted to keep my word to myself to eat healthy and make sure all the hard work I put in at the gym wouldnt go to waste by cheating too much on my diet. The gym also helped lift my mood and put me in a positive mindset when thinking about my weight-loss journey.

Usually my workouts consist of walking one-and-a-half or two miles on the treadmill, then doing 5 to 10 minutes on the StairMaster. After that, I will do some arms, abs, or legs.

I knew nothing about fitness and health before I had decided to seriously change my habits, but I became informed and dedicated. I went from a size 22 to a size 8. I am also happy to say, I no longer need that diabetes A1C medication. My blood work has come back at normal levels since losing so much weight.

I feel like a truly happy person on the inside, and so much healthier and free. I still enjoy my treats and my cheat meals in moderation, but I have found a new passion in my life. This journey made me realize how important self-love is regardless of size or weight. My weight and health were holding me back, and getting healthy was the best decision Ive ever made.

You Might Also Like

See the original post:
'I Lost 125 Lbs. With This Low-Carb Diet And Finally Got Off Diabetes Medication I Was On Since My Teens' - Yahoo Lifestyle

Posted in Diabetes | Comments Off on ‘I Lost 125 Lbs. With This Low-Carb Diet And Finally Got Off Diabetes Medication I Was On Since My Teens’ – Yahoo Lifestyle

Diabetes, hypertension top co-morbidities among COVID-19 fatalities – The Hindu

Posted: April 8, 2020 at 10:43 am

As many as 85% of those who died in the State due to COVID-19 had diabetes or hypertension or both, making their recovery difficult. Medical experts said these two conditions form an ideal background for pathogens like the SARS-CoV-2 to cause lethal damage.

According to data provided by State health officials till April 5, and analysed by The Hindu, of the 45 people who died, 38 had diabetes, hypertension or both. At least six victims also had heart disease.

Mumbai-based endocrinologist and diabetologist Dr. Shashank Joshi said, Our body has humoral mediated immunity, which helps in the formation of antibodies, and cellular mediated immunity, which is the bodys own defence mechanism. In patients with diabetes, these immune systems are weak.

This means they are immunocompromised, Dr. Joshi explained. He added, When a virus like the SARS-CoV-2 infects them, it causes a cytokine storm (an overproduction of immune cells and their activating compounds known as cytokines). This often leads to tremendous leaks into the lungs, which is why the patients require ventilators. Blood sugar and blood pressure parameters should be kept in control, he emphasised.

The International Diabetes Federation states that when people with diabetes develop a viral infection, it can be harder to treat due to fluctuations in blood glucose levels and, possibly, the presence of diabetes complications. There appear to be two reasons for this. Firstly, the immune system is compromised, making it harder to fight the virus and likely leading to a longer recovery period. Secondly, the virus may thrive in an environment of elevated blood glucose, the IDF states.

State officials also observed that the mortality rate was high among senior citizens. It was 19% in the 60-80 age group, and nearly 22% in the 80-90 age group. High blood pressure is common among the elderly. Age and other underlying ailments make them more vulnerable, said senior physician Dr Altaf Patel.

Physician and intensivist Dr. Pravin Amin said data from China and Italy also show a similar trend. Diabetes and hypertension alter the defence system and when a patient is affected by COVID-19, a network of reactions take place which become difficult to manage, said Dr. Amin adding that 80% of COVID-19 patients have very mild disease and with proper management, those with co-morbid conditions also show recovery. I have discharged a woman with diabetes on Sunday. The key is to have these diseases under control, said Dr. Amin who practices at Bombay Hosptal and Breach Candy Hospital.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

The rest is here:
Diabetes, hypertension top co-morbidities among COVID-19 fatalities - The Hindu

Posted in Diabetes | Comments Off on Diabetes, hypertension top co-morbidities among COVID-19 fatalities – The Hindu

There are countless reason to get interested in these stocks: :Tandem Diabetes Care, Inc., (NASDAQ: TNDM) – News Align

Posted: April 8, 2020 at 10:43 am

On Tuesday, Shares ofTandem Diabetes Care, Inc., (NASDAQ: TNDM), inclined/declined 63.09% and closed at $-6.16 in the last trading session.

Arithmetic Moving Averages TNDM:

Simple Moving Average (SMA) is easy to calculate and SMA20 one is principally looking at prime trends. The 50-day moving average is more responsive to price changes than the 200-day moving Whereas long-term trend followers generally use SMA200 and most shareholders will look for a cross up or down this average to means if the stock is in a bullish or bearish trend. SMA20 is the last stop on the bus for (ST) short-term traders. The Tandem Diabetes Care, Inc. having its distance from 20-days simple moving average is 6.57%, and its distance from 50-days simple moving average is -10.95%, while it has a distance of -3.00% from the 200-days simple moving average.

Working over theproductivity proportionsof business stock, the speculator will discover its ROE, ROA, ROI remaining at -15.80%, -9.10% and -8.70%, individually.

ATR remains at 6.28 while Beta component of the stock stands at 0.41. The beta component is used to check the eccentrics of the stock. The TNDM stock remained -1.96% unpredictable for the week and -10.13% for the month.

Market capitalization is only an extravagant proclaim for a bright idea: it is the market estimation of an organizations remarkable offers. These Amount and numbers are found by taking the postscript cost and increasing it by the all outnumber of offers remarkable. Understanding the market top isnt merely sign if you nearly putting legitimately in stocks. It is additionally helpful for common reserve speculators, the same number of assets will list the normal or middle showcase capitalization of its property. As the name recommends, this gives the centre-ground of the stores value speculations, filling financial specialists in as to whether the reserve, for the most part, puts resources into large, mid-or little top stocks.

Tandem Diabetes Care, Inc.Target:

The EPS of the company is strolling at -0.43. The companys Market capitalization is $3.95BBillion.

As stocks have aP/S,P/EandP/Bestimations of 10.90, 0.00 and 19.18 separately. Its P/Cash is esteemed at 22.37.

Development in profit per offer is everything. The healthy future development in profit per share (EPS) is an amazingly significant factor in recognizing an underestimated stock. The effect of income development is exponential. As time goes on, the cost of a stock will typically go up in lockstep with its income (accepting the P/E proportion is steady). Hence stocks with higher profit development should offer the most elevated capital increases. Whats more, doubling-up the growth more than doubles the capital gain, due to the compounding effect.

Volume & Average Volume Shares:

Volume of the Tandem Diabetes Care, Inc. exchanged hands with 1048551 shares compared to its average daily volume of 1.58M shares. Total volume is the number of shares or deals that point towards the whole activity of a security or market for a same period.

Post Views: 38

Continue reading here:
There are countless reason to get interested in these stocks: :Tandem Diabetes Care, Inc., (NASDAQ: TNDM) - News Align

Posted in Diabetes | Comments Off on There are countless reason to get interested in these stocks: :Tandem Diabetes Care, Inc., (NASDAQ: TNDM) – News Align

Understanding the Canadian Institutions of Health Research and Institute of Nutrition, Metabolism and Diabetes – Open Access Government

Posted: April 8, 2020 at 10:43 am

The Institute of Nutrition, Metabolism and Diabetes (INMD) is a branch of the Canadian Institutes of Health Research (CIHR). The CIHR Canadas federal funding for health research1, who collaborate with partners and researchers to find solutions that improve the healthcare system of Canada. This article concerns how, and if, the CIHR continuing to support excellence in health research is still their top priority, this will be done with a focus on the INMD.

The CIHRs role is to fund research that furthers the development of the Canadian healthcare system. For example, the CIHR have recently made a new line of funding available for researchers. This line of funding relates to stem cell-based therapies for Type 1 diabetes2. This new initiative will award funds to researchers in 2021, the 100th year anniversary of when two Canadian scientists (Drs Banting & McLeod) received a Nobel prize for the discovery of insulin. The CIHR states that Millions of lives have been saved due to this discovery, yet the prevalence of diabetes continues to increase and diabetes remains a chronic disease3. Therefore, they have announced this new initiative in order to ensure innovation continues within medical research in Canada.

The INMDs role specifically regards research into diet, digestion, excretion and metabolism. This is to ensure that they improve treatments relating to these areas as well as focussing on improving screening, prevention, diagnosis and support systems.

The current head of the INMD is Dr Norman Rosenblum, a professor of paediatrics, physiology, and laboratory medicine and pathobiology at the University of Toronto, and a paediatric nephrologist and senior scientist at the Research Institute of The Hospital for Sick Children4.

The CIHRs role is to fund research that furthers the development of the Canadian healthcare system. For example, the CIHR have recently made a new line of funding available for researchers. This line of funding relates to stem cell-based therapies for Type 1 diabetes.

An example of a research area that has recently been funded by the INMD are studies related to sugar intake and the resulting formulation of sugar reduction strategies based upon this research5. The CIHR, in conjunction with the INMD, have invested $2 million (Canadian Dollars), into this area of research in order to more effectively discourage excess sugar consumption6.

As a result of this funding there has been vital research regarding the sugar intake of Canadian children7, beverages containing artificial sweeteners8 and how nutrition labels and taxation could reduce sugar consumption9.

The INMD has three strategic research priorities:

The research listed in the previous paragraph pertains to the first and third strategic priorities but it is also important to discuss priority two when considering the full scope of the INMDs role and what research it funds. This priority concerns funding research that explores how environment and genes can exacerbate, or cause, chronic diseases.

As a result of this, the INMD fund research in this area via a series of grants referred to as: Programmatic Grants in Environments, Genes and Chronic Disease. Research that has been funded includes the following10:

The research listed within this article is evidence of the CIHR and INMDs commitment to positioning Canada as a leader of innovative health research in these areas. Being a global research leader is a top priority of the CIHR and it is one theyre achieving.

References1 https://cihr-irsc.gc.ca/e/193.html

2 https://cihr-irsc.gc.ca/e/51687.html

3 https://cihr-irsc.gc.ca/e/51687.html

4 https://cihr-irsc.gc.ca/e/12059.html

5 https://cihr-irsc.gc.ca/e/50611.html

6 ibid

7 https://cihr-irsc.gc.ca/e/50609.html

8 https://cihr-irsc.gc.ca/e/50601.html

9 https://cihr-irsc.gc.ca/e/50610.html

10 https://cihr-irsc.gc.ca/e/49868.html

Editor's Recommended Articles

View post:
Understanding the Canadian Institutions of Health Research and Institute of Nutrition, Metabolism and Diabetes - Open Access Government

Posted in Diabetes | Comments Off on Understanding the Canadian Institutions of Health Research and Institute of Nutrition, Metabolism and Diabetes – Open Access Government

FDA-Approved Randomized Controlled Feasibility Study Finds InGeneron’s Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder…

Posted: April 8, 2020 at 10:41 am

DetailsCategory: DNA RNA and CellsPublished on Tuesday, 07 April 2020 18:42Hits: 254

InGeneron announces publication of favorable results using regenerative cells isolated from patients own body fat prepared with the Transpose RT System in the Journal of Orthopaedic Surgery and Research.

HOUSTON, TX, USA I April 07, 2020 I Results of a U.S. FDA-approved, randomized controlled feasibility study on treatment of symptomatic partial-thickness rotator cuff tears (sPTRCT) with fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) are now available in the Journal of Orthopaedic Surgery and Research.

This prospective multicenter feasibility study performed by Sanford Health is the first randomized controlled trial in which cells isolated from patients own adipose tissue were compared to another therapy option for treating sPTRCT. Specifically, subacromial injection of corticosteroid was compared to injection of UA-ADRCs isolated from the subjects' own adipose tissue using InGeneron's Transpose RT System. Assessment at 24 and 52 weeks post treatment demonstrated significantly higher mean American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) total scores (indicating reduced pain and improved shoulder function) of the subjects in the UA-ADRC group compared to the subjects in the corticosteroid group at both time points. Additionally, there were no significant complications or adverse events associated with the injection of UA-ADRCs during a period of twelve months post treatment, with 20% of the subjects in the corticosteroid group experiencing full-thickness rotator cuff tears during the same period post treatment.

Based on the positive outcome of this feasibility study, InGeneron is currently enrolling a multi-center (up to 20 sites), nationwide FDA IDE pivotal study involving a significantly larger number of patients than the feasibility study (ClinicalTrials.gov Identifier: NCT03752827).

Symptomatic partial-thickness rotator cuff tears (sPTRCT) are among the most common injuries and ailments of the shoulder, especially in elderly patients. Subacromial corticosteroid injection, one of the standard therapies for sPTRCT, often leads to a temporary improvement in clinical symptoms, but not a cure. Furthermore, repeated subacromial corticosteroid injections were reported to be detrimental to tendon healing.

The study shows that unmodified, autologous ADRCs isolated from patients' own adipose tissue at point-of-care using InGenerons Transpose RT System represent a powerful and highly innovative alternative for treating symptomatic PTRCT, said Dr. John Furia, a board-certified orthopedic surgeon, who along with Dr. Nicola Maffulli (London, UK) served as clinical and scientific advisors. Injection of ADRCs into diseased tendons has the potential to jump-start the human response. The science is catching up with the hype and Im optimistic this modality will play an important role in how we treat our patients going forward."

The complete results of the study, entitled Safety and efficacy of treating symptomatic, partial-thickness rotator cuff tears with fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) isolated at the point of care: a prospective, randomized, controlled first-in-human pilot study, (DOI: https://doi.org/10.1186/s13018-020-01631-8) were published in the Journal of Orthopaedic Surgery and Research on March 30, 2020.

About the Transpose RT System and FDA approved clinical trials

InGeneron has developed the Transpose RT System, which consists of a processing unit, a set of disposables and Matrase, a unique enzyme mixture. The system allows isolation of UA-ADRCs from patients' own adipose tissue at point of care within approximately one hour. The UA-ADRCs are administered into the defect by injection under ultrasound guidance.

The Transpose RT System is currently being investigated under FDA IDE approval and accessible for research use only in the US. Currently, InGeneron has several active, FDA approved clinical trials utilizing the Transpose RT System that are enrolling. More information on these clinical trials can be found at http://www.clinicaltrials.gov under the identifiers NCT03752827, NCT03513731, and NCT03503305.

About InGeneron

InGeneron is a clinical stage cell therapy company enabling novel, safe and evidence-based regenerative medicine therapies. Our purpose is to set new therapeutic standards by developing treatments that unlock the healing potential of each patients own regenerative cells processed at the point of care for same-day application. We focus on helping patients who are impacted by musculoskeletal indications and are pursuing research to extend the application of our platform technology to additional treatment areas. http://www.ingeneron.com

SOURCE: InGeneron

Original post:
FDA-Approved Randomized Controlled Feasibility Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder...

Posted in Cell Therapy | Comments Off on FDA-Approved Randomized Controlled Feasibility Study Finds InGeneron’s Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder…

Covid-19 Impact on Cell Freezing Media for Cell Therapy Market (2020-2026) – Science In Me

Posted: April 8, 2020 at 10:41 am

The report titled Global Cell Freezing Media for Cell Therapy Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Cell Freezing Media for Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Cell Freezing Media for Cell Therapy market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Cell Freezing Media for Cell Therapy market is carefully analyzed and researched about by the market analysts.

Key companies operating in the global Cell Freezing Media for Cell Therapymarket include_BioLife Solutions, Thermo Fisher Scientific, Merck, GE Healthcare, Zenoaq, WAK-Chemie Medical, Biological Industries, Akron Biotechnology

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1548125/global-cell-freezing-media-for-cell-therapy-market

Segmental Analysis :

The report has classified the global Cell Freezing Media for Cell Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Cell Freezing Media for Cell Therapy manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Cell Freezing Media for Cell Therapy industry.

Global Cell Freezing Media for Cell Therapy Market Segment By Type:

With FBS, Without FBS

Global Cell Freezing Media for Cell Therapy Market Segment By Applications:

Human Embryonic Stem Cells, CAR-T Cell Therapy, Neural Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Hematopoietic Stem Cell Transplantation, Other

Critical questions addressed by the Cell Freezing Media for Cell Therapy Market report

Reasons to Buy the Report

Get Full Customize report now at :https://www.qyresearch.com/customize-request/form/1548125/global-cell-freezing-media-for-cell-therapy-market

Table of Contents1 Cell Freezing Media for Cell Therapy Market Overview1.1 Cell Freezing Media for Cell Therapy Product Overview1.2 Cell Freezing Media for Cell Therapy Market Segment by Type1.2.1 With FBS1.2.2 Without FBS1.3 Global Cell Freezing Media for Cell Therapy Market Size by Type (2015-2026)1.3.1 Global Cell Freezing Media for Cell Therapy Market Size Overview by Type (2015-2026)1.3.2 Global Cell Freezing Media for Cell Therapy Historic Market Size Review by Type (2015-2020)1.3.2.1 Global Cell Freezing Media for Cell Therapy Sales Market Share Breakdown by Type (2015-2026)1.3.2.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share Breakdown by Type (2015-2026)1.3.2.3 Global Cell Freezing Media for Cell Therapy Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Cell Freezing Media for Cell Therapy Market Size Forecast by Type (2021-2026)1.3.3.1 Global Cell Freezing Media for Cell Therapy Sales Market Share Breakdown by Application (2021-2026)1.3.3.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share Breakdown by Application (2021-2026)1.3.3.3 Global Cell Freezing Media for Cell Therapy Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.2 Europe Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.4 Latin America Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026) 2 Global Cell Freezing Media for Cell Therapy Market Competition by Company2.1 Global Top Players by Cell Freezing Media for Cell Therapy Sales (2015-2020)2.2 Global Top Players by Cell Freezing Media for Cell Therapy Revenue (2015-2020)2.3 Global Top Players Cell Freezing Media for Cell Therapy Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Cell Freezing Media for Cell Therapy Manufacturing Base Distribution, Sales Area, Product Type2.5 Cell Freezing Media for Cell Therapy Market Competitive Situation and Trends2.5.1 Cell Freezing Media for Cell Therapy Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Cell Freezing Media for Cell Therapy Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cell Freezing Media for Cell Therapy as of 2019)2.7 Date of Key Manufacturers Enter into Cell Freezing Media for Cell Therapy Market2.8 Key Manufacturers Cell Freezing Media for Cell Therapy Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Cell Freezing Media for Cell Therapy Status and Outlook by Region (2015-2026)3.1 Global Cell Freezing Media for Cell Therapy Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Cell Freezing Media for Cell Therapy Market Size Market Share by Region (2015-2020)3.2.1 Global Cell Freezing Media for Cell Therapy Sales Market Share by Region (2015-2020)3.2.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share by Region (2015-2020)3.2.3 Global Cell Freezing Media for Cell Therapy Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Cell Freezing Media for Cell Therapy Market Size Market Share by Region (2021-2026)3.3.1 Global Cell Freezing Media for Cell Therapy Sales Market Share by Region (2021-2026)3.3.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share by Region (2021-2026)3.3.3 Global Cell Freezing Media for Cell Therapy Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.4.1 North America Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.4.2 North America Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.5 Asia-Pacific Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.6 Europe Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.6.1 Europe Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.6.2 Europe Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.7 Latin America Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.7.1 Latin America Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.7.2 Latin America Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.8 Middle East and Africa Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026) 4 Global Cell Freezing Media for Cell Therapy by Application4.1 Cell Freezing Media for Cell Therapy Segment by Application4.1.1 Human Embryonic Stem Cells4.1.2 CAR-T Cell Therapy4.1.3 Neural Stem Cell Therapy4.1.4 Mesenchymal Stem Cell Therapy4.1.5 Hematopoietic Stem Cell Transplantation4.1.6 Other4.2 Global Cell Freezing Media for Cell Therapy Sales by Application: 2015 VS 2020 VS 20264.3 Global Cell Freezing Media for Cell Therapy Historic Sales by Application (2015-2020)4.4 Global Cell Freezing Media for Cell Therapy Forecasted Sales by Application (2021-2026)4.5 Key Regions Cell Freezing Media for Cell Therapy Market Size by Application4.5.1 North America Cell Freezing Media for Cell Therapy by Application4.5.2 Europe Cell Freezing Media for Cell Therapy by Application4.5.3 Asia-Pacific Cell Freezing Media for Cell Therapy by Application4.5.4 Latin America Cell Freezing Media for Cell Therapy by Application4.5.5 Middle East and Africa Cell Freezing Media for Cell Therapy by Application 5 North America Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)5.1.2 North America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)5.2.2 North America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)5.3.2 Canada Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 6 Europe Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)6.1.2 Europe Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)6.2.2 Europe Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.2 France Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.3 U.K. Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.4 Italy Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.5 Russia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 7 Asia-Pacific Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.2 Japan Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.3 South Korea Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.4 India Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.5 Australia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.6 Taiwan Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.7 Indonesia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.8 Thailand Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.9 Malaysia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.10 Philippines Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.11 Vietnam Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 8 Latin America Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)8.1.2 Latin America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)8.2.2 Latin America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)8.3.2 Brazil Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)8.3.3 Argentina Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 9 Middle East and Africa Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)9.3.3 U.A.E Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Cell Freezing Media for Cell Therapy Business10.1 BioLife Solutions10.1.1 BioLife Solutions Corporation Information10.1.2 BioLife Solutions Description, Business Overview and Total Revenue10.1.3 BioLife Solutions Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.1.4 BioLife Solutions Cell Freezing Media for Cell Therapy Products Offered10.1.5 BioLife Solutions Recent Development10.2 Thermo Fisher Scientific10.2.1 Thermo Fisher Scientific Corporation Information10.2.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue10.2.3 Thermo Fisher Scientific Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.2.5 Thermo Fisher Scientific Recent Development10.3 Merck10.3.1 Merck Corporation Information10.3.2 Merck Description, Business Overview and Total Revenue10.3.3 Merck Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.3.4 Merck Cell Freezing Media for Cell Therapy Products Offered10.3.5 Merck Recent Development10.4 GE Healthcare10.4.1 GE Healthcare Corporation Information10.4.2 GE Healthcare Description, Business Overview and Total Revenue10.4.3 GE Healthcare Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.4.4 GE Healthcare Cell Freezing Media for Cell Therapy Products Offered10.4.5 GE Healthcare Recent Development10.5 Zenoaq10.5.1 Zenoaq Corporation Information10.5.2 Zenoaq Description, Business Overview and Total Revenue10.5.3 Zenoaq Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.5.4 Zenoaq Cell Freezing Media for Cell Therapy Products Offered10.5.5 Zenoaq Recent Development10.6 WAK-Chemie Medical10.6.1 WAK-Chemie Medical Corporation Information10.6.2 WAK-Chemie Medical Description, Business Overview and Total Revenue10.6.3 WAK-Chemie Medical Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.6.4 WAK-Chemie Medical Cell Freezing Media for Cell Therapy Products Offered10.6.5 WAK-Chemie Medical Recent Development10.7 Biological Industries10.7.1 Biological Industries Corporation Information10.7.2 Biological Industries Description, Business Overview and Total Revenue10.7.3 Biological Industries Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.7.4 Biological Industries Cell Freezing Media for Cell Therapy Products Offered10.7.5 Biological Industries Recent Development10.8 Akron Biotechnology10.8.1 Akron Biotechnology Corporation Information10.8.2 Akron Biotechnology Description, Business Overview and Total Revenue10.8.3 Akron Biotechnology Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.8.4 Akron Biotechnology Cell Freezing Media for Cell Therapy Products Offered10.8.5 Akron Biotechnology Recent Development 11 Cell Freezing Media for Cell Therapy Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Cell Freezing Media for Cell Therapy Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Cell Freezing Media for Cell Therapy Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:
Covid-19 Impact on Cell Freezing Media for Cell Therapy Market (2020-2026) - Science In Me

Posted in Cell Therapy | Comments Off on Covid-19 Impact on Cell Freezing Media for Cell Therapy Market (2020-2026) – Science In Me

panCELLa receives research and development support for cell therapy – Yahoo Finance

Posted: April 8, 2020 at 10:41 am

TORONTO , April 7, 2020 /CNW/ - panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help further research and development of its technology platforms for cell therapy.

panCELLa Inc (CNW Group/panCELLa Inc.)

Support from NRC IRAP will go toward the research and development of a two-step safety switch known as panKiller. While panCELLa's safety switch, known as FailSafeTM, is specifically designed to eliminate only "rogue" or deregulated therapeutic cells, the panKiller system further enhances this platform and provides a means to remove a graft entirely once it has fulfilled its therapeutic purpose. When the therapeutic cells are no longer required, and to avoid serious adverse events, for further safety measures they would be eliminated using panKiller. The panKiller strategy is an effective solution that addresses serious limitations of current cell therapies which involve removal of these therapeutic cells through irradiation. panKiller will enable more prolonged, effective treatment in vivo; and will destroy the therapeutic cells at the appropriate time without the use of radiation to prevent the possibility of a malignancy.

About panCELLa

Founded in 2015, panCELLa is a privately-held early-stage biotechnology firm based on the innovative technology developed in Dr. Andras Nagy's lab at the Sinai Health System (SHS). panCELLa has created platforms that allow for the development of safe, universal, cost-effective, "off-the-shelf" cell lines. panCELLa's mandate is to accelerate cell-based therapies to a broad range of diseases by providing safe therapeutic cell products. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive FailSafeTM and Stealth CellsTM and its in-licensed SAFE harbor technology. panCELLa aims to develop therapeutic products in the immunology, mesenchymal stem cell and pancreatic islet space and to partner with other companies to develop novel products in other areas of regenerative medicine. panCELLa continues its internal R&D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination and tolerization. To learn more about panCELLa's FailSafeTM and induced Allogeneic Cell Tolerance, please visit https://pancella.com

SOURCE panCELLa Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2020/07/c5756.html

See more here:
panCELLa receives research and development support for cell therapy - Yahoo Finance

Posted in Cell Therapy | Comments Off on panCELLa receives research and development support for cell therapy – Yahoo Finance

Celularity and Infectious Disease Research Institute will try out COVID-19 cell therapy – GeekWire

Posted: April 8, 2020 at 10:41 am

Celularitys subsidiary, LifebankUSA, maintains a repository of placental and cord blood, containing stem cells for potential therapeutic use. (LifebankUSA / Robert Hariri via Twitter)

Seattles Infectious Disease Research Institute and a New Jersey company called Celularity have been cleared by the Food and Drug Administration to start trials of an experimental cell-based therapy for COVID-19.

The immunotherapy treatment makes use of natural killer cells, or NK cells, which play a key role in the bodys natural defense against viral infections. Celularitys NK cell product, known as CYNK-001, is derived from placental stem cells for treating viral diseases as well as some types of blood cancers and tumors.

CYNK-001 has been safely given to patients in early trials for treating leukemia and multiple myeloma. Now the FDA has given investigational new drug clearance for its use to be extended to COVID-19, the disease caused by the coronavirus outbreak.

To date, efforts to treat COVID-19 cases have been primarily focused on antiviral medications, Corey Casper, who is CEO of the Infectious Disease Research Institute as well as a clinical professor of global health at the University of Washington, explained in a news release.While these are important, patients with serious disease may not respond completely to antiviral medications because they are experiencing damage already inflicted on the bodys vital organs.

About 80 to 100 patients diagnosed with pneumonia due to a COVID-19 infection will be enrolled at medical centers in the U.S., potentially including sites in Washington state. Participants in the study will be provided with infusions of CYNK-001.

The hypothesis is that administering NK cells to patients with moderate to severe COVID-19 will allow the immune cells find the sites of active viral infection, kill the virus, and induce a robust immune response that will help heal the damage and control the infection, Casper said. Beyond its promise as a critically needed treatment for COVID-19, the biology of NK cells indicates a possibility that this immunotherapy could be used as an off-the-shelf treatment for future pandemic infections.

Initial results are expected about 30 to 60 days after the first patients receive the cells. If the results are encouraging, a more rigorous clinical trial would follow.

Last weekend, Rudy Giuliani, President Donald Trumps personal attorney, touted the treatment on Twitter, saying that this therapy has real potential. This week, the FDA gave its clearance for the preliminary tests on an expedited basis.

In a statement issued today, Celularitys chairman and CEO, Robert Hariri, thanked the FDAs Center for Biologics Evaluation and Research for their tireless effort to guide us through the process of clearing the drugs use for COVID-19.

The New York Times quoted Paul Knopfler, a stem cell researcher at the University of California at Davis, as saying that Celularitys approach carried some risk. Its conceivable that the NK cells could exacerbate problems by massive killing of the patients respiratory cells, he told the Times.

The FDA has cleared testing of several other therapies for COVID-19, including use of the drugs hydroxychloroquine and remdesivir as well as blood plasma from recovered patients. In addition, the first U.S. clinical trial of a COVID-19 vaccine is underway at Seattles Kaiser Permanente Washington Research Institute.

Read the original here:
Celularity and Infectious Disease Research Institute will try out COVID-19 cell therapy - GeekWire

Posted in Cell Therapy | Comments Off on Celularity and Infectious Disease Research Institute will try out COVID-19 cell therapy – GeekWire

Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients – The New York Times

Posted: April 8, 2020 at 10:41 am

At least one outside expert said the approach could present safety risks. Paul Knoepfler, a stem cell researcher at the University of California, Davis, said that patients with coronavirus can develop severe reactions where their immune systems go too far in attacking cells in their lungs, causing damaging inflammation. Other cell therapies tested in China are designed to dampen the immune response. He said one risk with the natural killer cells is they could go in the other direction, exacerbating respiratory problems by massive killing of the patients respiratory cells.

Despite the scant evidence, Mr. Giuliani has become an early booster, interviewing Dr. Hariri on a podcast published on his website Saturday, and praising the treatment on Twitter, saying, this therapy has real potential. In a tweet on Saturday, he added, Lets hope F.D.A. can recognize that their cumbersome process designed to keep us safer, if it is not altered dramatically in times of great need, can result in unimaginable loss of human life.

Around the same time, Twitter deleted a post by Mr. Giuliani that it said violated its rules. The tweet, from March 27, made unfounded claims about the malaria drug hydroxychloroquine, one of the treatments that Mr. Trump has supported.

Dr. Hariri said that he has known Mr. Giuliani for years and that the appearance on his podcast was a friendly chat between people who know each other and who share a common interest in this particular response to this disease.

He said that he has no business relationship with Mr. Giuliani, and that Mr. Giuliani is not representing him in any way, either paid or unpaid. I dont have anything to do with what the mayor tweets or whatnot, and I dont agree or disagree with anything, he said.

Dr. Hariri said the company would follow the established process for testing whether a drug works. We have waited for the F.D.A. to complete their review, which they did in a heroic and quick fashion, he said.

On Wednesday evening the same day the F.D.A. approved his trial Dr. Hariri praised the appearance by the agencys commissioner, Dr. Stephen Hahn, on the conservative Fox News talk show The Ingraham Angle.

We are fortunate to have Dr. Hahn at the helm, he tweeted.

Link:
Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients - The New York Times

Posted in Cell Therapy | Comments Off on Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients – The New York Times

Page 1,070«..1020..1,0691,0701,0711,072..1,0801,090..»